Current phase I/II clinical trials that engineer NK-92 cell lines with CARs to target CD19 (NCT02892695), CD33 (NCT02944162), CD7 (NCT02742727) on acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cells are ongoing. Here, CD19 is linked to acute lymphoblastic leukemia.